BOAN BIOTECH (06955) rose more than 6%. At the time of writing, the stock was up 6.28%, trading at HKD 9.98, with a turnover of HKD 49.8845 million. On the news front, on January 11, BOAN BIOTECH announced that its board of directors was pleased to announce that its self-developed Denosumab Injection (60mg) (R&D code: BA6101) had received marketing approval from the Bolivian National Agency for Medicines and Health Technologies (AGEMED). BA6101 is a biosimilar to the originator reference drug Prolia®, which is widely used globally for the treatment of osteoporosis. The indications for BA6101 are identical to those of the originator reference drug. BA6101 was developed based on the company's global R&D strategy and is planned for commercialization in numerous countries and regions worldwide. Currently, the Marketing Authorisation Application for BA6101 in the United Kingdom is under review, and the company plans to submit marketing applications in Europe, the United States, Japan, and other countries and regions.